fbpx Skip to main content

Low-dose IL-2 treatment may provide a new option for patients with chronic spontaneous urticaria who do not respond to traditional therapies.

Chronic spontaneous urticaria (CSU) can significantly impact patients’ quality of life, and a substantial proportion remains unresponsive to traditional therapies. While second-generation H1-antihistamines are the first-line treatment, they may only be effective for some patients, even at higher doses, and second- and third-line treatments, such as omalizumab and cyclosporine, have limitations.

Low-Dose IL-2 Treatment Holds Promise for Treating Multiple Diseases

In recent years, low-dose IL-2 treatment has been shown to be efficacious for the treatment of autoimmune diseases such as systemic lupus erythematosus, alopecia areata, chronic graft-versus-host disease, type 1 diabetes, and pemphigus. IL-2 may provide a novel treatment option for patients with CSU who do not respond to traditional therapies.

According to a recently published study in Clinical Immunology, low-dose IL-2 treatment has demonstrated the ability to improve disease control and alleviate symptoms for patients diagnosed with CSU who have not responded to H1-antihistamines.

Low-Dose IL-2 Treatment Confirmed Effective for CSU

In this retrospective study, researchers examined 15 patients with CSU who were resistant to antihistamine treatment and instead received low-dose IL-2 treatment. The results showed that 11 out of 15 patients (73.3%) experienced complete resolution of their symptoms at week 12, and 7 out of 15 patients (46.7%) achieved complete symptom resolution as early as the first follow-up at week 2.

Low-Dose Il-2 Treatment Was Highly Effective for Severe CSU

The number of patients with “severe” and “moderate” CSU decreased from 6 (40%) and 5 (33.3%) at the beginning of the study to 0 and 3 (20%) at Week 12, respectively. Only 3 out of 15 patients (20%) did not respond to the treatment.

You May Also Like::  Community Exposures Tied to SARS-CoV-2 Seropositivity in HCWs

Low-dose IL-2 treatment successfully ameliorated symptoms and achieved disease control in patients with CSU, resulting in a complete response rate of 73.3% over a 12-week period.

Source:

Wang, J., He, L., Yi, W., Liang, Q., Jiang, L., Tan, Y., Zhang, G., Su, Y., Xiao, R., Lu, Q., & Long, H. (2023). Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria. Clin Immunol, 247, 109247. https://doi.org/10.1016/j.clim.2023.109247

 

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.

#dermtwitter
@AADmember

New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More